{"id":"W4387811469","doi":"10.1016/j.annonc.2023.09.1841","title":"655O Phase Ib study of cofetuzumab pelidotin, an anti-PTK7 antibody-drug conjugate, in patients with PTK7-expressing recurrent non-small cell lung cancer (rNSCLC)","year":2023,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"Chugai Pharmaceutical; Pfizer Japan; EMD Serono; AstraZeneca; Genentech; Array BioPharma; LG Chem; Loxo Oncology; Sierra Oncology; Eisai; Y-mAbs Therapeutics; Taiho Pharmaceutical; EQRx; Lunit; Seagen; Relay Therapeutics; Ribon Therapeutics; Syndax Pharmaceuticals; City of Hope; Astellas Pharma; Fondazione Beretta; Incyte; Servier; Eli Lilly and Company; Calithera Biosciences; OncoMed Pharmaceutical; Boehringer Ingelheim Japan; Yuhan; Mersana Therapeutics; Daiichi Sankyo Europe; Agios Pharmaceuticals; BeiGene; Helsinn; Mirati Therapeutics; Amgen; Tizona Therapeutics; Jazz Pharmaceuticals; Regeneron Pharmaceuticals; Jounce Therapeutics; Ono Pharmaceutical; Takeda Pharmaceutical Company; AbbVie; Revolution Medicines; Exelixis; Sanofi; Pfizer; PharmaMar; Celgene; Bristol-Myers Squibb","keywords":"Medicine; Neutropenia; Internal medicine; Carboplatin; Gastroenterology; Oncology; Chemotherapy; Cisplatin","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004879099,0.0008011398,0.0008708611,0.0002604473,0.0002672488,0.0009212875,0.0003680377,0.0007242271,0.003225724],"category_scores_gemma":[0.0003071173,0.0003353955,0.001035375,0.000255518,0.0004921723,0.0003838262,0.0002042567,0.001383872,0.0009526768],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007168518,"about_ca_system_score_gemma":0.0009460223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002616685,"about_ca_topic_score_gemma":0.005902862,"domain_scores_codex":[0.9998254,0.00005297498,0.000008789191,0.0000304264,0.00001747844,0.00006484443],"domain_scores_gemma":[0.9998425,0.00001724566,0.00001825699,0.00001169384,0.00001098618,0.00009927779],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5515371,0.04549648,0.01899921,0.00123626,0.003283058,0.0006727871,0.0005190887,0.004713539,0.1303391,0.001048245,0.007196685,0.2349585],"study_design_scores_gemma":[0.3883713,0.5462605,0.03448951,0.00009881616,0.00147687,0.0008165753,0.0002340216,0.002871569,0.01268484,0.0003690179,0.01227135,0.00005550569],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.992523,0.002140663,0.000425008,0.0002874092,0.0001252872,0.0007790516,0.0007058549,0.00006724461,0.002946433],"genre_scores_gemma":[0.991945,0.001611302,0.0006282427,0.0004910738,0.00005652222,0.0004215458,0.001762301,0.00001751366,0.003066518],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003225724,"threshold_uncertainty_score":0.01079106,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05459332157448155,"score_gpt":0.4176143013310369,"score_spread":0.3630209797565553,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}